At a glance
ClinicalIndex Comparison RecordN/ACompleted· 237 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism
In Brief
An observational study for Chronic Kidney Failure and Secondary Hyperparathyroidism. Completed, enrolled 237 participants across 19 sites.
Detailed Summary
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedMar 2010
Primary CompletionFeb 2011
TodayJul 2026
First PostedMar 5, 2010
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.3 years ago